{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": "CDC_Influenza_vaccines",
  "additional_evidence_check": {
    "checked_for_more": true,
    "found_additional": false,
    "additional_count": 0
  },
  "completeness_stats": {
    "existing_evidence": 1,
    "new_evidence_found": 0,
    "total_evidence": 1
  },
  "combined_evidence": [
    {
      "id": 1,
      "quote": "Flublok Quadrivalent (RIV4) was evaluated in a pivotal clinical efficacy trial against a U.S.-licensed standard-dose, egg-based quadrivalent inactivated influenza vaccine (IIV4; Fluarix Quadrivalent, GSK) in adults aged \u226550 years.",
      "relevance_explanation": "This quote directly states that Flublok Quadrivalent was evaluated in a pivotal trial against Fluarix Quadrivalent, which is a standard-dose quadrivalent influenza vaccine, thus supporting the claim."
    }
  ],
  "completeness_assessment": {
    "missing_aspects": []
  },
  "model_used": "gpt-4.1"
}